Please ensure Javascript is enabled for purposes of website accessibility

Why Danaher Stock Soared in April

By Lee Samaha - May 4, 2021 at 9:41AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The life sciences and diagnostics company is a big winner of the COVID-19 pandemic.

What happened

Shares in life sciences and diagnostics company Danaher (DHR 1.79%) rose 12.8% in April, according to data provided by S&P Global Market Intelligence. An excellent set of first-quarter earnings drove the stock higher during the month. The company easily beat market expectations for the quarter and raised its full-year guidance. 

Danaher is one of the big winners of the COVID-19 pandemic, benefiting not only from a surge in revenue from sales of its COVID-19 diagnostic tests but also the company's life sciences tools, which are widely used by customers working on both vaccines and therapies.

Rows of vials labeled COVID-19 Vaccine

Image source: Getty Images.

With this in mind, it's no surprise that Danaher continues to report excellent numbers. However, it's also worth noting that management also raised full-year sales expectations for revenue not related to its COVID-19 solutions.

So what

Danaher is on track for a great 2021, but the more profound question is what happens in 2022 and beyond? Specifically, will Danaher be able to grow revenue as the pandemic subsides?

Investors can be optimistic on this front as its non-coronavirus revenue is growing at a high-single-digit clip in 2021. The company's overall revenue growth rate was in the mid single digits prior to the pandemic. Also, Danaher has been selling a lot of instrumentation and testing platforms due to the pandemic, which is opening up a new customer base for the company. Meanwhile, the global investment in vaccines could create an increased focus on vaccine research in the future.

Now what

Investors will be keeping an eye on the trajectory of both Danaher's pandemic-related revenue and its other revenue in 2021 and beyond. The former could benefit if there's a need for booster shots and children are cleared to receive vaccinations. In addition, the testing environment is unlikely to unwind anytime soon.

Meanwhile, its other revenue is partly a function of Danaher's ability to generate new business relationships due to the pandemic. The long-term future continues to look bright for the company.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Danaher Corporation Stock Quote
Danaher Corporation
$258.05 (1.79%) $4.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.